Immunology company Vir Biotechnology, Inc. (VIR) announced Wednesday that Mark Eisner will join the company as Executive Vice President and Chief Medical Officer (CMO), effective June 03, 2024.
Eisner will be a part of the company's Executive Management Team and will report directly to Chief Executive Officer Marianne De Backer.
Eisner brings to Vir deep immunology and infectious disease expertise with clinical development experience. He has an impressive track record of leading teams during times of strategically evolving portfolios.
Eisner comes from Sonoma Biotherapeutics, where he most recently held the position of CMO. Prior to his most recent tenure with Sonoma, Eisner served as CMO at FibroGen where he led all development functions, which included being the Head of China clinical development and clinical operations.
Eisner has also been with Genentech nearly 11 years and served as their Senior Vice President of Global Head of Product Development Immunology, Infectious Disease and Ophthalmology.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.